Only two eight drugs added to the list of vital drugs

The commission under the Ministry of Health has updated the list of vital drugs. Two drugs were included there – innovative drugs for the treatment of cancer – out of eight proposed. The analytical company « Right to Health » claims that the results of the meeting were « optimistic than expectations. » The All -Russian Union of Patients is expectedly dissatisfied with refusals.

On April 28, the Ministry of Health held the first meeting of the commission on the formation of the lists of vital drugs (GNLP) and 14 high -cost nosologies (VNS) in 2025. Medicines from these lists of citizens should be provided free of charge at the expense of the federal budget. The commission includes representatives of federal and regional ministries, specialized universities and scientific organizations. In addition, representatives of the pharmaceutical business and public associations may be present at meetings. Medical organizations, drug manufacturers, specialized NPOs and patient associations can offer drugs for inclusion in the lists.

This time, the commission considered eight applications for the List of GUNLP. Members of the commission Unanimously approved Lorlatinib drug (Lorvikva from Pfizer)that is used to treat Alk+ non -merciletic lung cancer. Representatives of the Blokhin Oncology NMIC said at the meeting that this medicine shows the “best results” for this type of cancer. About 200 people can be provided annually, and representatives of the All -Russian Union of Patients emphasized that we are talking about citizens of working age.

The commission also included Paigcetacoplan (Empaveli from Swedish Orphan Biovitrum AB)which is used in cancer for the treatment of paroxysmal night hemoglobinuria. The patient community noted that this is a “rescuing medicine” and non -alternative therapy for some patients.

The remaining six applications Commission Rejected. So, representatives of the NMHC named after Pirogov and NMIC of hematology proposed to include in the list asciminibus (antitumor drug for novartis)which is indicated for the treatment of chronic myeloid leukemia. According to experts, this is a unique, highly effective and safest drug for this nosology.

However, the Moscow depos sheet opposed, noting that the results of treatment are comparable to the effects of other drugs, while the price of asciminibus is higher.

Almost unanimously, members of the commission refused to include in the list:

• Trustuzumab Drucstecan (Enherto from Astrazeneca; is also used for the treatment of Her2-positive breast cancer with metastases and non-coclic lung cancer with a mutation in GER2),
• Tremelimumab (“Imjudo” from Astrazeneca; shown with inoperative hepatocellular cancer and metastatic non -coclucket lung cancer),
• Teklistamab (« Texpi » from Janssen; it is used for recurrent or refractory multiple myeloma).

Opinions were divided about Pharicigymab (Vabismo from Roche). This is the first bisperphynic antibody approved for the treatment of retinal diseases. Ophthalmologists noted the effectiveness of this medicine and the uniqueness of the mechanisms of its action – unlike other drugs, it can affect resistant forms of diseases. But the Ministry of Health, the Federal Fund of MHI and the Ministry of Industry and Trade indicated the existence of a similar Russian medicine Ranibizumab. As a result, 9 members of the commission voted for inclusion in the list, and 11 against.

Also from the List of the Zhnvlp were excluded in connection with the recall of registration Sarilumab preparations (used for therapy for rheumatoid arthritis and have no analogues) and Paginterferon alpha-2A (part of the first line therapy for chronic hepatitis B). They decided not to include in the list of VNS Siponymod (« Kayendra » from novartis)which is used to treat multiple sclerosis.

Olga Makarkina, General Director of the Right to Health Right to Health, explains that the inclusion in the lists provides the drug Ensinating the public procurement market – and in the practice of medical institutions throughout the country. The preliminary results of the meeting, according to its assessment, were more optimistic than expectations. “On the eve of the industry, relying on current trends and information from representatives of the authorities, they feared that due to the budget deficit, none of the presented drugs would be included in the list. Nevertheless, the commission has already voted for two flagship innovative drugs. This indicates that the position of the main freelance specialists and experts can be heard even in current realities, ”said Mrs. Makarkina.

At the same time, the commission confirmed the tendency to the priority of saving funds, the expert noted: manufacturers in accordance with the recommendations of regulators during the meeting reduced the cost of drugs in relation to the declared.

But this is not possible in all cases, which allows you to predict problems with the availability of innovative drug therapy in the country.

The co -chair of the All -Russian Union of Patients Yuri Zhulev “regrets” that the commission did not approve the majority of the drugs under consideration. Moreover, the main argument for refusal was the lack of approved clinical recommendations, he notes: “This causes serious concern. The approval of the Klinreks takes a long time, and until this happened, the drugs will not be included in the list of the GUNLP. Because of this, patients will have to seek the right to treatment through regional medical commissions. And it is extremely difficult to go through all the stages from the consideration of the patient application to the adoption of a positive decision and procurement – and takes a lot of precious in case of illness of time. ”

Natalia Kostarnova, Victoria Kolganova